Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366: l5021.

PubMed  Article  Google Scholar 

Rello J, Sabater-Riera J. Challenges in respiratory syncytial virus in adults with severe community-acquired pneumonia. Chest. 2022;161:1434–5.

PubMed  Article  Google Scholar 

Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18:82.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Food & Drug Administration. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull. 1986;16:7.

Google Scholar 

Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry [Internet]. US Food Drug Adm. 2017 [cited 2022 Mar 7]. Available from: https://search.usa.gov/search?affiliate=fda1&page=2&query=Ribavirin+AND+respiratory+syncitial+virus+infections&sort_by=

Malosh RE, Martin ET, Callear AP, Petrie JG, Lauring AS, Lamerato L, et al. Respiratory syncytial virus hospitalization in middle-aged and older adults. J Clin Virol. 2017;96:37–43.

PubMed  PubMed Central  Article  Google Scholar 

Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499–505.

CAS  PubMed  Article  Google Scholar 

Pierangeli A, Scagnolari C, Antonelli G. Respiratory syncytial virus. Minerva Pediatr. 2018;70:553–65.

PubMed  Article  Google Scholar 

Center for Drug Evaluation and Research. Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry [Internet]. US Food Drug Adm. FDA; 2019 [cited 2022 May 19]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance

EMA. Treatment and prophylaxis of respiratory syncytial virus (RSV) disease [Internet]. Eur. Med. Agency. 2018 [cited 2022 May 19]. Available from: https://www.ema.europa.eu/en/treatment-prophylaxis-respiratory-syncytial-virus-rsv-disease

Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56:258–66.

Manuel O, Estabrook M, American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13511.

Gross AE, Bryson ML. Oral Ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother. 2015;49:1125–35.

CAS  PubMed  Article  Google Scholar 

Avery L, Hoffmann C, Whalen KM. The use of aerosolized Ribavirin in respiratory syncytial virus lower respiratory tract infections in adult immunocompromised patients: a systematic review. Hosp Pharm. 2020;55:224–35.

PubMed  Article  Google Scholar 

de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, et al. Respiratory syncytial virus, human metapneumovirus, and parainfluenza virus infections in lung transplant recipients: a systematic review of outcomes and treatment strategies. Clin Infect Dis. 2022;74:2252–60.

PubMed  Article  CAS  Google Scholar 

Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222:S577–83.

CAS  PubMed  Article  Google Scholar 

Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:556–69.

PubMed  Article  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.

PubMed  Article  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Amsterdm: Wiley; 2019.

Book  Google Scholar 

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.

PubMed  PubMed Central  Article  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

PubMed  PubMed Central  Article  Google Scholar 

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ott. Hosp. Res. Inst. Nd. [cited 2022 Feb 2]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.

PubMed  PubMed Central  Article  Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

PubMed  PubMed Central  Article  Google Scholar 

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Testaert H, Bouet M, Valour F, Gigandon A, Lafon M-E, Philit F, et al. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study. Clin Microbiol Infect. 2021;27:897–903.

CAS  PubMed  Article  Google Scholar 

Martín-Cerezuela M, Cuéllar-Monreal MJ, Monte-Boquet E, Solé-Jover A, Poveda-Andrés JL. Oral ribavirin for treatment of respiratory syncytial virus in lung transplantation recipients. Transplant Proc. 2021;53:2702–5.

PubMed  Article  CAS  Google Scholar 

Lehners N, Schnitzler P, Geis S, Puthenparambil J, Benz MA, Alber B, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48:1548–53.

CAS  PubMed  Article  Google Scholar 

Balassa K, Salisbury R, Watson E, Lubowiecki M, Tseu B, Maouche N, et al. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation. J Infect. 2019;78:461–7.

PubMed  Article  Google Scholar 

Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402–12.

CAS  PubMed  Article  Google Scholar 

Azzi JM, Kyvernitakis A, Shah DP, El Haddad L, Mahajan SN, Ghantoji SS, et al. Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. J Antimicrob Chemother. 2018;73:3162–9.

CAS  PubMed  Article  Google Scholar 

Wongsurakiat P, Sunhapanit S, Muangman N. Respiratory syncytial virus-associated acute respiratory illness in adult non-immunocompromised patients: Outcomes, determinants of outcomes, and the effect of oral ribavirin treatment. Influenza Other Respir Viruses. 2022;16:767–79.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88:1222–6.

PubMed  Article  Google Scholar 

Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:321–7.

CAS  PubMed  Article  Google Scholar 

Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92:1216–23.

PubMed  Article  Google Scholar 

Everard ML, Swarbrick A, Rigby AS, Milner AD. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. Respir Med. 2001;95:275–80.

CAS  PubMed  Article  Google Scholar 

Diseases AC on I. Red Book (2012): Report of the Committee on Infectious Diseases [Internet]. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012 [cited 2022 Apr 27]. Available from: https://publications.aap.org/aapbooks/book/603/Red-Book-2012-Report-of-the-Committee-on

Hebert MF, Guglielmo BJ. What is the clinical role of aerosolized ribavirin? DICP Ann Pharmacother. 1990;24:735–8.

CAS  Google Scholar 

Glanville AR, Scott AIR, Morton JM, Aboyoun CL, Plit ML, Carter IW, et al. Intravenous Ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–9.

PubMed  Article  Google Scholar 

Beaird OE, Freifeld A, Ison MG, Lawrence SJ, Theodoropoulos N, Clark NM, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18:210–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mejias A, Ramilo O. New options in the treatment of respiratory syncytial virus disease. J Infect. 2015;71:S80–7.

PubMed  Article  Google Scholar 

Pareek R, Murphy R, Harrison L, Cook R, DeVincenzo J. 954: Invitro superiority of RSV Fusion Inhibitor MDT-637 vs. ribavirin predicts improved clinical benefit. Crit Care Med. 2013;41:A239–40.

Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, et al. Oral versus aerosolized Ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68:1641–9.

CAS  PubMed  Article  Google Scholar 

Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018;20: e12844.

PubMed  Article  CAS  Google Scholar 

Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31:839–44.